• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov14
Douglas Tsao Maintains Hold Rating on Outlook Therapeutics
23:41
Sep29
Outlook Therapeutics Completes Type A Meeting with FDA
13:37
Aug15
Outlook Therapeutics released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 1.505 M (forecast USD 1.663 M), actual EPS USD -0.5499 (forecast USD -0.3525)
03:00
Outlook Therapeutics released FY2025 9 Months Earnings on August 14 EST, with actual revenue of USD 1.505 M and EPS of USD -1.3343
03:00
Jul1
Outlook Therapeutics Appoints Bob Jahr as CEO
12:06
Jun2
Outlook Therapeutics Launches First Bevacizumab Ophthalmic Formulation in Germany and the UK
11:44

Schedules & Filings

Schedules
Filings
Aug14
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 1.505 M, Net Income -20.15 M, EPS -0.5499

May15
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -46.36 M, EPS -1.5014

Feb14
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income 17.38 M, EPS 0.717

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
TGL
25.866
+282.75%
+19.192
SMX
344.642
+144.43%
+203.642
WHLR
6.330
+95.37%
+3.085
GURE
8.881
+87.36%
+4.120
TDIC
0.4226
+50.50%
+0.142
DBRG
14.535
+49.54%
+4.795
LICN
4.230
+44.37%
+1.300
TORO
5.600
+35.59%
+1.470
ALMS
11.160
+34.46%
+2.860
RIME
1.965
+33.67%
+0.495
View More